Answers are grounded in this paper and cite their sources.
In patients with early, relapsing-remitting multiple sclerosis, alemtuzumab was more effective than interferon beta-1a but was associated with autoimmunity, most seriously manifesting as immune thrombocytopenic purpura. The study was not powered to identify uncommon adverse events. (ClinicalTrials.gov number, NCT00050778.)
No takes yet. Share an insight, caveat, or question.
The CAMMS Trial Investigators (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: